Shanghai RAAS Blood Products Valuation

Q: What is the Fair Price of 002252 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002252 (CN¥7.65) is trading above our estimate of [[fair value]] (CN¥0.92)

Is 002252 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002252 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002252 (CN¥7.65) is trading above our estimate of fair value (CN¥0.92)

Significantly Below Fair Value: 002252 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002252?

Key metric: As 002252 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002252. This is calculated by dividing 002252's market cap by their current earnings.
What is 002252's PE Ratio?
PE Ratio	27.6x
Earnings	CN¥1.83b
Market Cap	CN¥50.00b

002252 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.5x
Enterprise Value/EBITDA	19.3x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does 002252's PE Ratio compare to its peers?

The above table shows the PE ratio for 002252 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	27x
600161 Beijing Tiantan Biological Products	34.3x	19.7%	CN¥43.2b
300896 Imeik Technology DevelopmentLtd	32.1x	18.2%	CN¥64.9b
301301 Yili Chuanning BiotechnologyLtd	22.1x	14.9%	CN¥30.2b
300122 Chongqing Zhifei Biological Products	19.6x	45.1%	CN¥71.7b
002252 Shanghai RAAS Blood Products	27.6x	17.0%	CN¥50.0b

Price-To-Earnings vs Peers: 002252 is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the peer average (27x).

Price to Earnings Ratio vs Industry

How does 002252's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002252 is good value based on its Price-To-Earnings Ratio (27.6x) compared to the CN Biotechs industry average (36.6x).

Price to Earnings Ratio vs Fair Ratio

What is 002252's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002252 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.6x
Fair PE Ratio	29.7x

Price-To-Earnings vs Fair Ratio: 002252 is good value based on its Price-To-Earnings Ratio (27.6x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002252 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥7.65	CN¥6.40 -16.3%	6.3%	CN¥6.80	CN¥6.00	n/a	2
Nov ’25	CN¥7.35	CN¥6.40 -12.9%	6.3%	CN¥6.80	CN¥6.00	n/a	2
Oct ’25	CN¥7.90	CN¥6.55 -17.1%	8.4%	CN¥7.10	CN¥6.00	n/a	2
Sep ’25	CN¥7.17	CN¥6.55 -8.6%	8.4%	CN¥7.10	CN¥6.00	n/a	2
Aug ’25	CN¥7.70	CN¥6.55 -14.9%	8.4%	CN¥7.10	CN¥6.00	n/a	2
Jul ’25	CN¥7.96	CN¥6.55 -17.7%	8.4%	CN¥7.10	CN¥6.00	n/a	2
Jun ’25	CN¥7.10	CN¥6.55 -7.7%	8.4%	CN¥7.10	CN¥6.00	n/a	2
Mar ’25	CN¥7.26	CN¥8.04 +10.7%	12.9%	CN¥9.08	CN¥7.00	n/a	2
Feb ’25	CN¥6.44	CN¥8.04 +24.8%	12.9%	CN¥9.08	CN¥7.00	n/a	2
Jan ’25	CN¥8.00	CN¥8.04 +0.5%	12.9%	CN¥9.08	CN¥7.00	n/a	2

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

-3.9%

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

-2.0%

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥22.24

2.3%

23.4%